A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus.

Melissa E MunroeDerek BlankenshipDaniele DeFreeseMohan PurushothamanWade DeJagerSusan MacwanaJoel M GuthridgeStan KampNancy RedingerTeresa AberleEliza F ChakravartyCristina ArriensYanfeng LiHu ZengKathleen A McCarthy-FruinShirley-Ann Osei-OnomahmUma ThanarajasingamJudith A JamesEldon Jupe

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

We verified altered immune mediators associated with imminent disease flare; a subset improved the FRI to identify SLE patients at risk of imminent flare. This molecularly-informed proactive management approach could be critical in prospective clinical trials and the clinical management of lupus.

Keyphrases

systemic lupus erythematosus
clinical trial
disease activity
rheumatoid arthritis
randomized controlled trial
study protocol